MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTX Price/Volume Stats
| Current price | $6.58 | 52-week high | $11.57 |
| Prev. close | $6.30 | 52-week low | $4.77 |
| Day low | $6.13 | Volume | 128,400 |
| Day high | $6.70 | Avg. volume | 151,281 |
| 50-day MA | $5.80 | Dividend yield | N/A |
| 200-day MA | $7.10 | Market Cap | 391.51M |
MGTX Stock Price Chart Interactive Chart >
MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio
MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.
Latest MGTX News From Around the Web
Below are the latest news stories about MEIRAGTX HOLDINGS PLC that investors may wish to consider to help them evaluate MGTX as an investment opportunity.
Wall Street Analysts Predict a 314.29% Upside in MeiraGTx Holdings PLC (MGTX): Here's What You Should KnowThe consensus price target hints at a 314.3% upside potential for MeiraGTx Holdings PLC (MGTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual MeetingMultiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, which is being held from May 16-20, 2023, in Los Angeles, CA. “Our presentation |
MeiraGTx Reports First Quarter 2023 Financial and Operational ResultsRaised approximately $60 million in a private placement in May 2023 with investors consisting of several of the Company’s top shareholders On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) in 2024Company will present 12-month data from bilateral treated cohorts from the AQUAx AAV-hAQP1 Phase 1 study for treatment of Grade 2/3 radiation-induced xerostomia in the second quarter of 2023Upcoming poster pr |
MeiraGTx Announces $60 Million Private Placement of Ordinary SharesLONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $60 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gen |
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual MeetingLONDON and NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced two abstract presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting. The first abstract will present humoral immune response data from the Company’s Phase 1/2 MGT009 trial for the investigational gene therapy botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) in patients with |
MGTX Price Returns
| 1-mo | 22.99% |
| 3-mo | -14.10% |
| 6-mo | 6.30% |
| 1-year | -20.05% |
| 3-year | -56.28% |
| 5-year | N/A |
| YTD | 0.92% |
| 2022 | -72.54% |
| 2021 | 56.80% |
| 2020 | -24.38% |
| 2019 | 107.68% |
| 2018 | N/A |
Loading social stream, please wait...